Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The paper presents a fragment of a systemic study on the efficiency of replacing inorganic salts of microelements in guaranteed mineral premixes used in quail feed with a complex supplement of said elements in nanocitrate form produced by Nanomaterials and Nanotechnologies LLC (Kyiv). The study is, in particular, focused on the levels of microelements (Mn, Zn, Cu, Fe, Co, І) in quails and their egg yolks depending on the form and concentration of those microelements in the poultry diet. The tests have been conducted on 14-day old Pharaoh quails divided into three groups. Raising conditions – cages. Test duration – 2 months. Quails of all groups were fed complete feed with a balanced content of nutrients and biologically active compounds. Control group birds were given mineral premix containing inorganic salts of (g/t of feed): Mn – 50, Zn ‒ 50, Cu ‒ 2.5, Fe ‒10, Co ‒1 and І ‒ 0.7. Test group quails were fed a mineral complex of aqua citrates of the same elements with a concentration of (calculated for each element) 1/10 (D1) and 1/20 (D2) or 10 and 5 % of their content in a standard mineral premix (SP). It is established that the form and dosage of microelements introduced into the diet affect their levels in quails and their egg yolks. Nanocitrates of bioelements have a relatively high cumulative potential in poultry compared with the control group (an inorganic form of microelements). The best results are achieved with citrate elements being fed in a concentration of 10% of their regular content in a standard mineral premix. It is proven that the use of optimal concentration of aqua citrates of microelements in poultry diet promotes increased levels of manganese, iron, zinc, copper and cobalt (Р < 0.05‒0.001) in the liver and hip muscles as well as iron and copper levels (Р < 0.01‒0.001) in breast muscles of quails; increased body weight by 15.7 % during the testing period; an enhanced biological value of the eggs (increased calcium (Р < 0.05), iodine (Р < 0.05), zinc (Р < 0.01) levels) compared to analogs in the control group.
The paper presents a fragment of a systemic study on the efficiency of replacing inorganic salts of microelements in guaranteed mineral premixes used in quail feed with a complex supplement of said elements in nanocitrate form produced by Nanomaterials and Nanotechnologies LLC (Kyiv). The study is, in particular, focused on the levels of microelements (Mn, Zn, Cu, Fe, Co, І) in quails and their egg yolks depending on the form and concentration of those microelements in the poultry diet. The tests have been conducted on 14-day old Pharaoh quails divided into three groups. Raising conditions – cages. Test duration – 2 months. Quails of all groups were fed complete feed with a balanced content of nutrients and biologically active compounds. Control group birds were given mineral premix containing inorganic salts of (g/t of feed): Mn – 50, Zn ‒ 50, Cu ‒ 2.5, Fe ‒10, Co ‒1 and І ‒ 0.7. Test group quails were fed a mineral complex of aqua citrates of the same elements with a concentration of (calculated for each element) 1/10 (D1) and 1/20 (D2) or 10 and 5 % of their content in a standard mineral premix (SP). It is established that the form and dosage of microelements introduced into the diet affect their levels in quails and their egg yolks. Nanocitrates of bioelements have a relatively high cumulative potential in poultry compared with the control group (an inorganic form of microelements). The best results are achieved with citrate elements being fed in a concentration of 10% of their regular content in a standard mineral premix. It is proven that the use of optimal concentration of aqua citrates of microelements in poultry diet promotes increased levels of manganese, iron, zinc, copper and cobalt (Р < 0.05‒0.001) in the liver and hip muscles as well as iron and copper levels (Р < 0.01‒0.001) in breast muscles of quails; increased body weight by 15.7 % during the testing period; an enhanced biological value of the eggs (increased calcium (Р < 0.05), iodine (Р < 0.05), zinc (Р < 0.01) levels) compared to analogs in the control group.
Проведено исследование влияния антиоксидантной терапии селеносодержащим препаратом Про-Визио (Unimed Pharma, Словакия) на электрофизиологические показатели сетчатки и прогрессирование миопии у детей с разным состоянием тонуса вегетативной нервной системы. Обнаружено превалирование ваготонии при высокой миопии, что сопровождается ранним началом заболевания (средний возраст детей 7,861,29 года), чем при симпатикотонии (13,41,63 года, p0,02), а также более быстрым ее прогрессированием. Средний показатель миопии по сферическому эквиваленту у детей с ваготонией в нашем исследовании составил 9,840,82 Д, а с симпатикотонией 6,910,16 Д (p0,005). Для миопии слабой и средней степени такой закономерности выявлено не было. Добавление к лечению селеносодержащего препарата с антиоксидантными свойствами Про-Визио позволило достоверно улучшить электрофизиологические показатели сетчатки, в том числе и через 6 месяцев наблюдений: у детей со слабой и средней степенью миопии разница между исходным уровнем критической частоты исчезновения мельканий по фосфену (КЧИМФ) и показателем, полученным через полгода, составила в основной группе 7,300,35 Гц, а в контрольной 2,910,98 (p0,002). Для порогов электрической чувствительности по фосфену (ПЭЧФ) разница составила 7,772,01 мА в основной и 0,900,87 в контрольной группе (p0,005). В группе пациентов с высокой миопией через 6 месяцев после лечения сохранилось повышение КЧИМФ на 5,891,10 Гц в основной группе и на 0,71,2 в контрольной (p0,01), а улучшение ПЭЧФ на 12,262,74 мА и 1,92,16 мА соответственно (p0,01). Прогрессирование миопии в течение 6 месяцев в обеих группах было незначительным, однако абсолютные показатели удлинения глазного яблока оказались выше в контрольной группе. Особенно выраженным оказался положительный эффект у пациентов с высокой миопией на фоне ваготонии: улучшение КЧИМФ через 6 месяцев после лечения по сравнению с показателями до лечения составило 2,70,81 Гц при симпатикотонии и 7,811,01 при парасимпатикотонии (p0,002). Положительная динамика ПЭЧФ соответственно 8,191,16 и 14,703,48 мА (p0,005). Включение в комплексное лечение препарата Про-Визио в рекомендованных дозах (1 раз в день по таблетки детям с 3 до 12 лет и 1 таблетка детям старше 12 лет) длительными курсами (до 3 месяцев) оказало положительное влияние на показатели состояния сетчатки у детей с миопией, препарат хорошо переносился и не оказывал побочных эффектов. The aim of our work was to study effect of antioxidant therapy with selenium-containing medicine Pro-Visio (Unimed Pharma, Slovakia) on the retinal electrophysiological parameters and myopia progression in children with different types of the autonomic nervous system: with predominance of parasympathetic (PSNS) or sympathetic (SNS) type. PSNS predominance was observed in children with high myopia, that was accompanied both with early onset of the disease (average age of children is 7.861.29) compared to SNS (13.41.63 years, p0.02), and with more rapid progression. The average spherical equivalent of myopia in children with PSNS predominance in our study was 9.840.82 D, while with SNS 6.910.16 D (p0.005). In patients with mild and moderate myopia this relation was not revealed. Use of selenium-containing antioxidant medicine Pro-Visio in complex therapy allowed to improve electrophysiological retinal parameters the obtained results were also significant in 6 months af- ter the therapy: the difference between the phosphene critical frequency of flicker disappearance (PCFFD) at the start and finish of observation (after 6 months) in mild and moderate myopia chil- dren was 7.300.35 Hz in the main group, and 2.910.98 in the control (p0.002). For phosphene electrical sensitivity thresholds (PEST) the difference was 7.772.01 mA in the main, and 0.900.87 in the control group (p0,005). In the high myopia patients improvement of PCFFD after 6-months therapy was 5.891.10 Hz in the main group, and 0.71.2 in the control one (p0.01), improvement of PEST was 12.262.74 mA and 1.92.16 мА respectively (p0.01). Myopia progression for 6 months in both groups was insignificant however the absolute data of the eyeball elongation were higher in the control group. The positive effect was more obvious in patients with high myopia and PSNS predominance: the PCFFD improvement in 6 months therapy compared to pre-treatment results was 2.70.81 Hz in SNS patients versus 7.811.01 in PSNS group (p0.002). The positive dynamics of PEST was 8.191.16 and 14.703.48 mA respectively (p0.005). Use of selenium-containing antioxidant medicine Pro-Visio in complex therapy in recommended dosage (once a day pills in children of 3-12 years of age and 1 pill in children over 12 years old) for 3 months had positive effect on retinal function in children with myopia. The medicine was well tolerated and did not demonstrate any side effects.
Проведено исследование влияния антиоксидантной терапии селеносодержащим препаратом Про-Визио (Unimed Pharma, Словакия) на электрофизиологические показатели сетчатки и прогрессирование миопии у детей с разным состоянием тонуса вегетативной нервной системы.Обнаружено превалирование ваготонии при высокой миопии, что сопровождается ранним началом заболевания (средний возраст детей 7,86±1,29 года), чем при симпатикотонии (13,4±1,63 года, p<0,02), а также более быстрым ее прогрессированием. Средний показатель миопии по сферическому эквиваленту у детей с ваготонией в нашем исследовании составил 9,84±0,82 Д, а с симпатикотонией – 6,91±0,16 Д (p<0,005). Для миопии слабой и средней степени такой закономерности выявлено не было.Добавление к лечению селеносодержащего препарата с антиоксидантными свойствами Про-Визио позволило достоверно улучшить электрофизиологические показатели сетчатки, в том числе и через 6 месяцев наблюдений: у детей со слабой и средней степенью миопии разница между исходным уровнем критической частоты исчезновения мельканий по фосфену (КЧИМФ) и показателем, полученным через полгода, составила в основной группе 7,30±0,35 Гц, а в контрольной – 2,91±0,98 (p<0,002). Для порогов электрической чувствительности по фосфену (ПЭЧФ) разница составила 7,77±2,01 мА в основной и 0,90±0,87 в контрольной группе (p<0,005). В группе пациентов с высокой миопией через 6 месяцев после лечения сохранилось повышение КЧИМФ на 5,89±1,10 Гц в основной группе и на 0,7±1,2 в контрольной (p<0,01), а улучшение ПЭЧФ – на 12,26±2,74 мА и 1,9±2,16 мА соответственно (p<0,01).Прогрессирование миопии в течение 6 месяцев в обеих группах было незначительным, однако абсолютные показатели удлинения глазного яблока оказались выше в контрольной группе. Особенно выраженным оказался положительный эффект у пациентов с высокой миопией на фоне ваготонии: улучшение КЧИМФ через 6 месяцев после лечения по сравнению с показателями до лечения составило 2,7±0,81 Гц при симпатикотонии и 7,81±1,01 при парасимпатикотонии (p<0,002). Положительная динамика ПЭЧФ соответственно 8,19±1,16 и 14,70±3,48 мА (p<0,005). Включение в комплексное лечение препарата Про-Визио в рекомендованных дозах (1 раз в день по ½ таблетки детям с 3 до 12 лет и 1 таблетка детям старше 12 лет) длительными курсами (до 3 месяцев) оказало положительное влияние на показатели состояния сетчатки у детей с миопией, препарат хорошо переносился и не оказывал побочных эффектов. The aim of our work was to study effect of antioxidant therapy with selenium-containing medicine Pro-Visio (Unimed Pharma, Slovakia) on the retinal electrophysiological parameters and myopia progression in children with different types of the autonomic nervous system: with predominance of parasympathetic (PSNS) or sympathetic (SNS) type.PSNS predominance was observed in children with high myopia, that was accompanied both with early onset of the disease (average age of children is 7.86±1.29) compared to SNS (13.4±1.63 years, p<0.02), and with more rapid progression. The average spherical equivalent of myopia in children with PSNS predominance in our study was 9.84±0.82 D, while with SNS 6.91±0.16 D (p<0.005). In patients with mild and moderate myopia this relation was not revealed.Use of selenium-containing antioxidant medicine Pro-Visio in complex therapy allowed to improve electrophysiological retinal parameters; the obtained results were also significant in 6 months af- ter the therapy: the difference between the phosphene critical frequency of flicker disappearance (PCFFD) at the start and finish of observation (after 6 months) in mild and moderate myopia chil- dren was 7.30±0.35 Hz in the main group, and 2.91±0.98 in the control (p<0.002). For phosphene electrical sensitivity thresholds (PEST) the difference was 7.77±2.01 mA in the main, and 0.90±0.87 in the control group (p<0,005). In the high myopia patients improvement of PCFFD after 6-months therapy was 5.89±1.10 Hz in the main group, and 0.7±1.2 in the control one (p<0.01), improvement of PEST was 12.26±2.74 mA and 1.9±2.16 мА respectively (p<0.01).Myopia progression for 6 months in both groups was insignificant however the absolute data of the eyeball elongation were higher in the control group.The positive effect was more obvious in patients with high myopia and PSNS predominance: the PCFFD improvement in 6 months therapy compared to pre-treatment results was 2.7±0.81 Hz in SNS patients versus 7.81±1.01 in PSNS group (p<0.002). The positive dynamics of PEST was 8.19±1.16 and 14.70±3.48 mA respectively (p<0.005).Use of selenium-containing antioxidant medicine Pro-Visio in complex therapy in recommended dosage (once a day ½ pills in children of 3-12 years of age and 1 pill in children over 12 years old) for 3 months had positive effect on retinal function in children with myopia. The medicine was well tolerated and did not demonstrate any side effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.